Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Issue 5 (May 2022)

• Record Type: Journal Article
• Authors: Makker, Vicky; Colombo, Nicoletta; Herráez, Antonio Casado; Santin, Alessandro D.; Colomba, Emeline; Miller, David S.; Fujiwara, Keiichi; Pignata, Sandro; Baron-Hay, Sally; Ray-Coquard, Isabelle; Shapira-Frommer, Ronnie; Ushijima, Kimio; Sakata, Jun; Yonemori, Kan; Kim, Yong Man; Guerra, Eva M.; Sanli, Ulus A.; McCormack, Mary M.; Smith, Alan D.; Keefe, Stephen; Bird, Steven; Dutta, Lea; Orlowski, Robert J.; Lorusso, Domenica
• Is Part Of: Obstetrical & gynecological survey. Volume 77:Issue 5(2022)
• Page Start: 275
• Page End: 276
• Publication Date: 2022-05
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/OGX.0000000000001032
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from N Engl J Med 2022;386:437–448) Little consensus exists on optimal treatment for advanced or recurrent endometrial cancer after disease progression with platinum-based chemotherapy. Lenvatinib is a multitargeted tyrosine kinase inhibitor that as a single agent has demonstrated limited efficacy as second-line treatment of recurrent endometrial carcinoma.